Remimazolam Besylate
FDA-approved product (powder, intravenous), marketed as Byfavo.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Sedation
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Benzodiazepine derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredEnoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Remimazolam Besylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
NCT06124404 · start 2022-04-08
Registered record
- Registry ID
- NCT06124404
- Conditions
- Mechanically Ventilated Patients
- Interventions
- Remimazolam besylate; Remimazolam besylate; Remimazolam besylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2022-04-08
- Completion
- 2023-02-28
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMechanically Ventilated PatientsInterventionRemimazolam besylate; Remimazolam besylate; Remimazolam besylatePhasePhase 2Registry statusCompletedEndoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding
NCT05554965 · start 2022-02-10
Registered record
- Registry ID
- NCT05554965
- Conditions
- Endoscopic Hemostasis; Sedation
- Interventions
- Propofol; Remimazolam besylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2022-02-10
- Completion
- 2022-12-30
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndoscopic Hemostasis; SedationInterventionPropofol; Remimazolam besylatePhasePhase 4Registry statusUnknownRemimazolam and Propofol Anesthesia in Elderly Patients
NCT05201300 · start 2022-02-02
Registered record
- Registry ID
- NCT05201300
- Conditions
- Hemodynamics
- Interventions
- Remimazolam Besylate 6 mg/kg/hr; Remimazolam Besylate 12 mg/kg/hr; Propofol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-02-02
- Completion
- 2023-01-18
- Enrolment
- 69
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemodynamicsInterventionRemimazolam Besylate 6 mg/kg/hr; Remimazolam Besylate 12 mg/kg/hr; PropofolPhaseNot applicableRegistry statusCompletedThe Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients
NCT04947345 · start 2021-09-01
Registered record
- Registry ID
- NCT04947345
- Conditions
- Analgesia; Postoperative Pain
- Interventions
- Remimazolam Besylate; Propofol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2021-09-01
- Completion
- 2022-09-01
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnalgesia; Postoperative PainInterventionRemimazolam Besylate; PropofolPhasePhase 3Registry statusUnknownEfficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Mechanically Ventilated ICU Patients
NCT04790734 · start 2021-05-10
Registered record
- Registry ID
- NCT04790734
- Conditions
- Critical Illness
- Interventions
- Sedation drugs
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-05-10
- Completion
- 2022-05-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCritical IllnessInterventionSedation drugsPhasePhase 2Registry statusCompleted